MCM
PLRX icon

Moore Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Moore Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-27,000
Closed -$489K – 573
2023
Q2 		$489K Buy
+27,000
New +$639K 0.01% 351

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Moore Capital Management's PLRX Position: Q3 2023 in Review

Moore Capital Management sold out of Pliant Therapeutics (PLRX) in Q3 2023, closing a stake of 27,000 shares — an estimated $489K sold.

Moore Capital Management first reported a position in PLRX in Q2 2023 and held it in 1 quarter. The position peaked at $489K in Q2 2023. 136 funds tracked by Wall St. Rank hold PLRX as of Q3 2023.

  • Moore Capital Management reported no remaining Pliant Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Moore Capital Management sold 27,000 Pliant Therapeutics shares in Q3 2023, an estimated $489K.
  • Moore Capital Management first reported a position in Pliant Therapeutics in Q2 2023 and held it in 1 quarter.
  • Moore Capital Management's Pliant Therapeutics position peaked at $489K in Q2 2023.
  • 136 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2023.

Based on Moore Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.